Related Experiment Video
Updated: Sep 20, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.8K
Summary
Circulating tumor DNA analysis from liquid biopsies can guide chemotherapy decisions for stage II colon cancer patients post-surgery. This approach may also reveal resistance mechanisms to KRASG12C inhibitors for improved cancer therapies.
Area of Science:
- Oncology
- Molecular Diagnostics
- Gastrointestinal Cancers
Background:
- Stage II colon cancer treatment typically involves surgery, with adjuvant chemotherapy decisions based on risk stratification.
- Identifying patients who benefit from chemotherapy remains a clinical challenge.
- Emerging liquid biopsy technologies offer non-invasive monitoring of cancer.
Purpose of the Study:
- To evaluate the utility of circulating tumor DNA (ctDNA) analysis in guiding adjuvant chemotherapy decisions for stage II colon cancer.
- To explore the role of ctDNA in understanding resistance mechanisms to targeted therapies like KRASG12C inhibition.
Main Methods:
- Phase II clinical trial (DYNAMIC study) involving patients with stage II colon cancer.
- Analysis of circulating tumor DNA (ctDNA) in blood samples (liquid biopsies).
- Correlation of ctDNA status with treatment outcomes and resistance patterns.
Main Results:
- ctDNA analysis demonstrated potential in identifying patients who could safely forgo chemotherapy after surgery.
- Liquid biopsies provided insights into the emergence of resistance to KRASG12C inhibitors.
Conclusions:
- Circulating tumor DNA testing may personalize adjuvant treatment strategies for stage II colon cancer.
- Liquid biopsies represent a promising tool for monitoring treatment response and overcoming resistance in colorectal cancer.
